Trimethylamine oxide: a potential target for heart failure therapy

Area of Science:

• Cardiovascular Disease
• Gut Microbiome Research
• Metabolic Pathways

Background:

• Heart failure (HF) is a significant cardiovascular disease with high mortality and rehospitalization rates.
• Pathophysiological understanding of HF has evolved from fluid retention to neuroendocrine activation.
• The Human Microbiome Project has highlighted the role of intestinal microecology in disease development and drug efficacy.

Purpose of the Study:

• To explore the link between intestinal microecology, trimethylamine N-oxide (TMAO) production, and heart failure (HF) prognosis.
• To investigate the potential of targeting TMAO metabolism for novel HF therapeutic strategies.
• To update the understanding and treatment concepts for HF based on the gut-HF hypothesis.

Main Methods:

• Review of existing literature on HF pathophysiology, gut microbiome, and TMAO metabolism.
• Analysis of the metabolic pathway from dietary choline and L-carnitine to TMAO via intestinal microflora and hepatic FMO enzymes.
• Correlation of circulating TMAO levels with HF progression, mortality, and readmission rates.

Main Results:

• Dietary compounds are metabolized by gut microbes into trimethylamine (TMA), which is converted to TMAO in the liver.
• Elevated circulating TMAO levels are associated with adverse outcomes in HF patients.
• TMAO concentration increases as HF progresses, indicating a poorer prognosis.

Conclusions:

• The gut microbiome plays a crucial role in TMAO production, a metabolite linked to adverse HF outcomes.
• Intervening in intestinal microflora or relevant enzymes to reduce TMAO levels is a promising research area for HF treatment.
• Targeting TMAO metabolism represents a potential paradigm shift in managing heart failure, improving therapeutic effects and patient prognosis.